We provide key assumptions for the forecast of Broncus' financials and pre-money valuation. The company is fairly valued based on forward EV/Sales metric, despite its unique pulmonary portfolio.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.